Stock Scorecard
Stock Summary for Scynexis Inc (SCYX) - $0.77 as of 10/27/2025 3:59:52 PM EST
Total Score
10 out of 30
Safety Score
27 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for SCYX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for SCYX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for SCYX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for SCYX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for SCYX (27 out of 100)
| Stock Price Rating (Max of 10) | 1 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 8 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for SCYX
Financial Details for SCYX
Company Overview |
|
|---|---|
| Ticker | SCYX |
| Company Name | Scynexis Inc |
| Country | USA |
| Description | Scynexis Inc. is a biotechnology firm headquartered in Jersey City, New Jersey, specializing in innovative therapies for the treatment of invasive fungal infections, with a particular focus on serious yeast infections. The company’s lead product candidate, BREXAFEMME®, is the first oral therapeutic specifically indicated for the treatment of vulvovaginal candidiasis, representing a significant advancement in antifungal therapy. With a robust pipeline and a commitment to addressing unmet medical needs in infectious diseases, Scynexis is well-positioned to enhance its market presence within the evolving landscape of antifungal treatments. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - SPECIALTY & GENERIC |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/5/2025 |
Stock Price History |
|
| Last Day Price | 0.77 |
| Price 4 Years Ago | 6.10 |
| Last Day Price Updated | 10/27/2025 3:59:52 PM EST |
| Last Day Volume | 268,379 |
| Average Daily Volume | 594,459 |
| 52-Week High | 1.49 |
| 52-Week Low | 0.66 |
| Last Price to 52 Week Low | 16.67% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 90.73 |
| Sector PE | 41.00 |
| 5-Year Average PE | -2.07 |
| Free Cash Flow Ratio | 2.96 |
| Industry Free Cash Flow Ratio | 13.74 |
| Sector Free Cash Flow Ratio | 29.25 |
| Current Ratio Most Recent Quarter | 5.20 |
| Total Cash Per Share | 0.26 |
| Book Value Per Share Most Recent Quarter | 1.14 |
| Price to Book Ratio | 0.75 |
| Industry Price to Book Ratio | 11.41 |
| Sector Price to Book Ratio | 32.16 |
| Price to Sales Ratio Twelve Trailing Months | 9.91 |
| Industry Price to Sales Ratio Twelve Trailing Months | 2.79 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.80 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 41,924,900 |
| Market Capitalization | 32,282,173 |
| Institutional Ownership | 31.87% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -131.75% |
| Reported EPS 12 Trailing Months | -0.40 |
| Reported EPS Past Year | -0.25 |
| Reported EPS Prior Year | -0.44 |
| Net Income Twelve Trailing Months | -19,517,000 |
| Net Income Past Year | -21,288,000 |
| Net Income Prior Year | 67,041,000 |
| Quarterly Revenue Growth YOY | 85.30% |
| 5-Year Revenue Growth | 98.68% |
| Operating Margin Twelve Trailing Months | -701.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 11,020,000 |
| Total Cash Past Year | 16,051,000 |
| Total Cash Prior Year | 34,050,000 |
| Net Cash Position Most Recent Quarter | -1,139,000 |
| Net Cash Position Past Year | 3,892,000 |
| Long Term Debt Past Year | 12,159,000 |
| Long Term Debt Prior Year | 12,159,000 |
| Total Debt Most Recent Quarter | 12,159,000 |
| Equity to Debt Ratio Past Year | 0.82 |
| Equity to Debt Ratio Most Recent Quarter | 0.79 |
| Total Stockholder Equity Past Year | 55,077,000 |
| Total Stockholder Equity Prior Year | 72,962,000 |
| Total Stockholder Equity Most Recent Quarter | 44,467,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -24,102,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.57 |
| Free Cash Flow Past Year | -24,009,000 |
| Free Cash Flow Prior Year | 0 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.04 |
| MACD Signal | -0.03 |
| 20-Day Bollinger Lower Band | 0.56 |
| 20-Day Bollinger Middle Band | 0.82 |
| 20-Day Bollinger Upper Band | 1.09 |
| Beta | 1.68 |
| RSI | 39.32 |
| 50-Day SMA | 0.97 |
| 150-Day SMA | 1.70 |
| 200-Day SMA | 2.07 |
System |
|
| Modified | 10/25/2025 9:01:44 AM EST |